SoftBank Partners with TempusAI to Establish Joint Venture in Japan

TapTechNews June 28th news, the SoftBank Group released a press release on the 27th local time, announcing the establishment of a joint venture SBTEMPUSCorp. with TempusAI, an enterprise in the field of artificial intelligence and precision medicine.

Each party will invest 15 billion yen (TapTechNews note: currently about 681 million yuan) in the joint venture respectively. The company will start its operation in August, aiming to provide precision medical services in Japan and provide treatment plans suitable for patients by integrating the images and clinical data owned by Japanese and American hospitals.

According to the introduction, the joint venture will utilize the 7.7 million cancer patients data owned by Tempus and combine the data collected from major hospitals in Japan to launch the service as soon as possible within the year. In order to help as many cancer patients as possible, the two sides will establish cooperative relationships with cancer genomic medicine hospitals, Japanese hospitals and medical institutions, pharmaceutical companies, biotech companies, medical device companies, cancer insurance companies and testing companies to provide support for better diagnosis and treatment.

The CEO of SoftBank, Masayoshi Son, said that by promoting the use of advanced personalized medicine with AI, he strongly hopes to reduce people's pain and increase people's happiness as much as possible.